13F Holdings
中文EN

PTCT PTC THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1070081 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-35.1%
TTM net income YoY-114.1%
TTM EPS YoY-115.5%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin12.8%
Net margin-9.2%
FCF margin0.2%
EBITDA margin18.1%

Returns

ROE—
ROA-3.6%
ROIC (approx.)—
Asset turnover0.39x

Leverage & solvency

Liabilities / assets106.0%
Debt / equity—
Current ratio3.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.10x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.73B$806.78M$937.82M$698.80M$538.59M
R&D expense$455.25M$534.48M$666.56M$651.50M$540.68M
SG&A expense$347.14M$300.91M$332.54M$326.00M$285.77M
Operating income$866.93M-$302.57M-$439.50M-$447.41M-$374.44M
Pretax income$696.62M-$363.12M-$696.11M-$587.49M-$518.34M
Income tax$13.97M$176,000-$69.51M-$28.47M$5.56M
Net income$682.64M-$363.30M-$626.60M-$559.02M-$523.90M
EBITDA$905.75M-$226.91M-$202.91M-$318.57M-$310.31M
EPS (basic)8.58-4.73-8.37-7.79-7.43
EPS (diluted)7.78-4.73-8.37-7.79-7.43
Weighted avg. shares (diluted)88.31M76.85M74.84M71.73M70.47M
Balance sheet
Cash & equivalents$984.65M$795.32M$610.28M$295.93M$197.22M
Short-term investments$960.72M$359.99M$282.74M$130.87M$583.66M
Receivables$181.62M$158.55M$160.82M$155.61M$110.45M
Inventory$79.65M$23.19M$30.58M$21.81M$15.86M
Current assets$2.27B$1.37B$1.22B$693.78M$954.37M
PP&E, net$55.37M$60.97M$87.09M$72.59M$52.59M
Goodwill$82.34M$82.34M$82.34M$82.34M$82.34M
Intangibles$388.75M$118.79M$379.50M$705.89M$724.84M
Total assets$2.90B$1.71B$1.90B$1.71B$1.94B
Current liabilities$968.43M$580.98M$603.10M$406.24M$509.35M
Short-term debt$286.63M———$149.54M
Long-term debt—$285.41M$284.21M$571.72M$281.89M
Total debt—$285.41M$284.21M$571.72M$431.43M
Total liabilities$3.10B$2.80B$2.71B$2.05B$1.94B
Shareholders' equity-$205.31M-$1.10B-$818.55M-$347.09M$1.44M
Net debt—-$509.90M-$326.07M$275.80M$234.22M
Shares outstanding81.47M77.70M75.71M73.10M70.83M
Cash flow statement
Operating cash flow$711.20M-$107.69M-$158.42M-$356.65M-$251.33M
Capital expenditure$8.86M$6.50M$28.44M$32.02M$28.21M
Free cash flow$702.34M-$114.19M-$186.86M-$388.67M-$279.55M
Investing cash flow-$861.98M$44.18M-$176.74M$290.18M$219.18M
Financing cash flow$331.09M$255.87M$646.40M$167.95M$20.88M
Depreciation & amortization$38.81M$75.66M$236.59M$128.84M$64.13M
Stock-based compensation$74.55M$74.61M$101.64M$110.33M$103.51M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.